Involvement of calpain and p25 of CDK5 pathway in ginsenoside Rb1's attenuation of β-amyloid peptide25-35-induced tau hyperphosphorylation in cortical neurons

Brain Research

Volumn 1200, Issue , 2008, Pages 99-106

  Chen, Xiaochun ^a   Huang, Tianwen ^a   Zhang, Jing ^a   Song, Jinqiu ^a   Chen, Limin ^a   Zhu, Yuangui ^a  

^a BEIJING HOSPITAL   (China)

Author keywords

amyloid (A ); Cyclin dependent kinase 5 (CDK5); Ginsenoside Rb1; p25; p35; Tau

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; CALCIUM ION; CALPAIN; CYCLIN DEPENDENT KINASE 5; GINSENOSIDE RB 1; PROTEIN P25; ROSCOVITINE; TAU PROTEIN;

ANIMAL CELL; ARTICLE; BRAIN NERVE CELL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EMBRYO; NERVE CELL CULTURE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; CALCIUM; CALCIUM SIGNALING; CALPAIN; CELLS, CULTURED; CEREBRAL CORTEX; CYTOSKELETON; DRUGS, CHINESE HERBAL; GINSENOSIDES; MICROTUBULES; NERVE TISSUE PROTEINS; NEUROFIBRILLARY TANGLES; NEURONS; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TAU PROTEINS;

EID: 40849125462     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2007.12.029     Document Type: Article

References (43)

1. Alvarez A., Toro R., Caceres A., and Maccioni R.B. Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloid-induced neuronal death. FEBS Lett. 459 (1999) 421-426
2. Alvarez A., Munoz J.P., and Maccioni R.B. A Cdk5-p35 stable complex is involved in the beta-amyloid-induced deregulation of Cdk5 activity in hippocampal neurons. Exp Cell Res 264 (2001) 266-274
3. Billingsley M.L., and Kincaid R.L. Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem, J. 323 Pt 3 (1997) 577-591
4. Busciglio J., Lorenzo A., Yeh J., and Yankner B.A. beta-Amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 14 (1995) 879-888
5. Chen X.C., Chen L.M., Zhu Y.G., Fang F., Zhou Y.C., and Zhao C.H. Involvement of CDK4, pRB, and E2F1 in ginsenoside Rg1 protecting rat cortical neurons from beta-amyloid-induced apoptosis. Acta Pharmacol. Sin. 24 (2003) 1259-1264
6. Cheng Y., Shen L.H., and Zhang J.T. Anti-amnestic and anti-aging effects of ginsenoside Rg1 and Rb1 and its mechanism of action. Acta Pharmacol. Sin. 26 (2005) 143-149
7. Dhavan R., and Tsai L.H. A decade of CDK5. Nat. Rev. Mol. Cell Biol 2 (2001) 749-759
8. Ferreira A., Lu Q., Orecchio L., and Kosik K.S. Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar A beta. Mol. Cell Neurosci. 9 (1997) 220-234
9. Filgueira de Azevedo W., Gaspar R.T., Canduri F., Camera J.C., and Freitas da Silveira N.J. Molecular model of cyclin-dependent kinase 5 complexed with roscovitine. Biochem. Biophys. Res. Commun. 297 (2002) 1154-1158
10. Fujita K., Hakuba N., Hata R., Morizane I., Yoshida T., Shudou M., Sakanaka M., and Gyo K. Ginsenoside Rb1 protects against damage to the spiral ganglion cells after cochlear ischemia. Neurosci. Lett. 415 2 (2007) 113-117
11. Goedert M. Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci. 16 (1993) 460-465
12. Goedert M. Neurofibrillary pathology of Alzheimer's disease and other tauopathies. Prog. Brain Res. 117 (1998) 287-306
13. Grynkiewicz G., Poenie M., and Tsien R.Y. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260 (1985) 3440-3450
14. Humbert S., Dhavan R., and Tsai L. p39 activates cdk5 in neurons, and is associated with the actin cytoskeleton. J. Cell Sci. 113 Pt 6 (2000) 975-983
15. Hung K.S., Hwang S.L., Liang C.L., Chen Y.J., Lee T.H., Liu J.K., Howng S.L., and Wang C.H. Calpain inhibitor inhibits p35-p25-Cdk5 activation, decreases tau hyperphosphorylation, and improves neurological function after spinal cord hemisection in rats. J. Neuropathol. Exp. Neurol. 64 1 (2005) 15-26
16. Ino H., Ishizuka T., Chiba T., and Tatibana M. Expression of CDK5 (PSSALRE kinase), a neural cdc2-related protein kinase, in the mature and developing mouse central and peripheral nervous systems. Brain Res. 661 (1994) 196-206
17. Jiang X.Y., Zhang J.T., and Shi C.Z. Mechanism of action of ginsenoside Rb1 in decreasing intracellular Ca2+. Acta Pharmaceutica. Sinica. 31 (1996) 321-326
18. Kawahara M., and Kuroda Y. Intracellular calcium changes in neuronal cells induced by Alzheimer's beta-amyloid protein are blocked by estradiol and cholesterol. Cell Mol. Neurobiol. 21 (2001) 1-13
19. Kusakawa G., Saito T., Onuki R., Ishiguro K., Kishimoto T., and Hisanaga S. Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. J. Biol. Chem. 275 (2000) 17166-17172
20. Lee K.Y., Clark A.W., Rosales J.L., Chapman K., Fung T., and Johnston R.N. Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain. Neurosci. Res. 34 (1999) 21-29
21. Lee M.S., Kwon Y.T., Li M., Peng J., Friedlander R.M., and Tsai L.H. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405 (2000) 360-364
22. Lee V.M., Goedert M., and Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24 (2001) 1121-1159
23. Li G., Faibushevich A., Turunen B.J., Yoon S.O., Georg G., Michaelis M.L., and Dobrowsky R.T. Stabilization of the cyclin-dependent kinase 5 activator, p35, by paclitaxel decreases beta-amyloid toxicity in cortical neurons. J. Neurochem. 84 (2003) 347-362
24. Li Y.K., Chen X.C., Zhu Y.G., Peng X.S., Zeng Y.Q., Sheng J., and Huang T.W. Ginsenoside Rb1 attenuates okadaic acid-induced Tau protein hyperphosphorylation in rat hippocampal neurons. Sheng Li Xue Bao 57 (2005) 154-160
25. Liu M., and Zhang J. Effects of ginsenoside Rb1 and Rg1 on synaptosomal free calcium level, ATPase and calmodulin in rat hippocampus. Chin. Med. J. (Engl) 108 (1995) 544-547
26. Mattson M.P., Cheng B., Davis D., Bryant K., Lieberburg I., and Rydel R.E. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12 (1992) 376-389
27. Mook-Jung I., Hong H.S., Boo J.H., Lee K.H., Yun S.H., Cheong M.Y., Joo I., Huh K., and Jung M.W. Ginsenoside Rb1 and Rg1 improve spatial learning and increase hippocampal synaptophysin level in mice. J. Neurosci. Res. 63 (2001) 509-515
28. Morishima-Kawashima M., Hasegawa M., Takio K., Suzuki M., Yoshida H., Titani K., and Ihara Y. Proline-directed and non-proline-directed phosphorylation of PHF-tau. J. Biol. Chem. 270 (1995) 823-829
29. Nath R., Davis M., Probert A.W., Kupina N.C., Ren X., Schielke G.P., and Wang K.K. Processing of cdk5 activator p35 to its truncated form (p25) by calpain in acutely injured neuronal cells. Biochem. Biophys. Res. Commun. 274 (2000) 16-21
30. Pascale A., and Etcheberrigaray R. Calcium alterations in Alzheimer's disease: pathophysiology, models and therapeutic opportunities. Pharmacol. Res. 39 (1999) 81-88
31. Patrick G.N., Zhou P., Kwon Y.T., Howley P.M., and Tsai L.H. p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway. J. Biol. Chem. 273 (1998) 24057-24064
32. Patrick G.N., Zukerberg L., Nikolic M., de la Monte S., Dikkes P., and Tsai L.H. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402 (1999) 615-622
33. Radad K., Gille G., Moldzio R., Saito H., and Rausch W.D. Ginsenosides Rb1 and Rg1 effects on mesencephalic dopaminergic cells stressed with glutamate. Brain Res. 1021 1 (2004) 41-53
34. Sakanaka M., Zhu P., Zhang B., Wen T.C., Cao F., Ma Y.J., Samukawa K., Mitsuda N., Tanaka J., Kuramoto M., Uno H., and Hata R. Intravenous infusion of dihydroginsenoside Rb1 prevents compressive spinal cord injury and ischemic brain damage through upregulation of VEGF and Bcl-XL. J. Neurotrauma. 24 6 (2007) 1037-1054
35. Smith D.S., Greer P.L., and Tsai L.H. Cdk5 on the brain. Cell Growth Differ. 12 (2001) 277-283
36. Smith W.W., Gorospe M., and Kusiak J.W. Signaling mechanisms underlying Abeta toxicity: potential therapeutic targets for Alzheimer's disease. CNS Neurol. Disord. Drug Targets 5 (2006) 355-561
37. Sobue K., Agarwal-Mawal A., Li W., Sun W., Miura Y., and Paudel H.K. Interaction of neuronal Cdc2-like protein kinase with microtubule-associated protein tau. J. Biol. Chem. 275 (2000) 16673-16680
38. Tsai L.H., Takahashi T., Caviness Jr. V.S., and Harlow E. Activity and expression pattern of cyclin-dependent kinase 5 in the embryonic mouse nervous system. Development 119 (1993) 1029-1040
39. Tsai L.H., Delalle I., Caviness Jr. V.S., Chae T., and Harlow E. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 371 (1994) 419-423
40. Yuan Q.L., Yang C.X., Xu P., Gao X.Q., Deng L., Chen P., Sun Z.L., and Chen Q.Y. Neuroprotective effects of ginsenoside Rb1 on transient cerebral ischemia in rats. Brain Res. 1167 (2007) 1-12
41. Zhang D.S., and Zhang J.T. Effects of total ginsenoside on learning and memory impairment induced by beta-amyloid peptide (25-35). Chin Pharmacol Bull. 16 (2000) 422-425
42. Zheng M., Leung C.L., and Liem R.K. Region-specific expression of cyclin-dependent kinase 5 (cdk5) and its activators, p35 and p39, in the developing and adult rat central nervous system. J. Neurobiol. 35 (1998) 141-149
43. Zheng Y.L., Li B.S., Amin N.D., Albers W., and Pant H.C. A peptide derived from cyclin-dependent kinase activator (p35) specifically inhibits Cdk5 activity and phosphorylation of tau protein in transfected cells. Eur. J. Biochem. 269 (2002) 4427-4434